Phase I Dose Finding and Pharmacokinetic Study of Intravenous APO010, a Recombinant Form of Human Fas Ligand, in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2015
At a glance
- Drugs APO 010 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Onxeo SA; TopoTarget Switzerland
- 12 Mar 2009 Planned end date changed from 1 Dec 2007 to 1 Oct 2009 as reported by ClinicalTrials.gov.
- 13 Nov 2007 New trial record.